收藏产品 产品信息
抗体来源（Source）
FMC63 scFv, His Tag is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.
种属（Species）
Mouse
亚型（Isotype）
C-10×His
偶联（Conjugate）
Unconjugated
抗体类型（Antibody Type）
scFV
种属反应性（Reactivity）
Human
免疫原（Immunogen）
CD19.
特异性（Specificity）
Specifically recognizes the antigen-recognition domain of CD19-derived CARs.
应用（Application）
| Application | Recommended Usage |
| ELISA | 5-125 ng/mL |
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
纯化（Purification）
Protein A purified / Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
产品数据图
电泳（SDS-PAGE）
FMC63 scFv, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of FMC63 scFv, His Tag (Cat. No. CD9-M52Hb) is more than 90% and the molecular weight of this protein is around 25-37 kDa verified by SEC-MALS.
Report
活性（Bioactivity）-ELISA
Immobilized Human CD19 (20-291), Fc Tag, premium grade (Cat. No. CD9-H5251) at 5 μg/mL (100 μL/well) can bind FMC63 scFv, His Tag (Cat. No. CD9-M52Hb) with a linear range of 0.005-0.156 μg/mL (QC tested).
Protocol
产品评论 发表评论
背景
FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.
数据表和文档 
联系我们 
项目合作